D Gareth R Evans

Summary

Country: UK

Publications

  1. ncbi Neurofibromatosis type 2 (NF2): a clinical and molecular review
    D Gareth R Evans
    Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Central Manchester Foundation Trust, St Mary s Hospital, Manchester M130JH, UK
    Orphanet J Rare Dis 4:16. 2009
  2. ncbi Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]
    D Gareth R Evans
    Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Manchester University and Central Manchester Foundation Trust, St Mary s Hospital, Hathersage Road, Manchester M13 0JH, United Kingdom
    Genet Med 11:599-610. 2009
  3. ncbi Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification
    D Gareth R Evans
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester, UK
    J Med Genet 44:424-8. 2007

Collaborators

Detail Information

Publications3

  1. ncbi Neurofibromatosis type 2 (NF2): a clinical and molecular review
    D Gareth R Evans
    Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Central Manchester Foundation Trust, St Mary s Hospital, Manchester M130JH, UK
    Orphanet J Rare Dis 4:16. 2009
    ..In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating condition...
  2. ncbi Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]
    D Gareth R Evans
    Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Manchester University and Central Manchester Foundation Trust, St Mary s Hospital, Hathersage Road, Manchester M13 0JH, United Kingdom
    Genet Med 11:599-610. 2009
    ..In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating, life limiting condition...
  3. ncbi Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification
    D Gareth R Evans
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester, UK
    J Med Genet 44:424-8. 2007
    ..Neurofibromatosis type 2 (NF2) is almost unique among inherited disorders in the frequency of mosaicism in the first affected generation. However, the implications of this on transmission risks have not been fully elucidated...